Nomura Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

By Carrie Williams

In a report issued on December 16, Christopher Marai from Nomura maintained a Buy rating on Sarepta Therapeutics (SRPTResearch Report), with a price target of $230.00. The company’s shares closed last Monday at $128.22.

According to TipRanks.com, Marai is a 4-star analyst with an average return of 6.5% and a 51.4% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protagonist Therapeutics, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $204.69, implying a 56.6% upside from current levels. In a report issued on December 2, H.C. Wainwright also assigned a Buy rating to the stock with a $160.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $158.80 and a one-year low of $72.05. Currently, Sarepta Therapeutics has an average volume of 1.43M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.